The most influential Megatrends set to shape the world through 2030, identified by Euromonitor International, help businesses better anticipate market developments and lead change for their industries.
Learn moreEuromonitor addresses your unique questions and challenges across all B2B and B2C industries and geographies through custom, tailor-made research projects, designed to your specific goals.
Learn moreOct 2019
US$990Added to Cart
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
Although current value sales recorded a modest increase in 2019, paediatric consumer health will continue to be dampened by two factors. The first is the expected decline in the birth rate, which is expected to continue in the long term.
As with other categories in consumer health, the performance of paediatric consumer health can also be affected by “bad years” in terms of ailments. For example, a mild or short winter, such as 2018 and 2019, results in lower levels of ailments and therefore more limited impetus behind sales in paediatric analgesics and cough, cold and allergy remedies, for example.
The switch towards more natural substances is even stronger in paediatric consumer health than in products for adults, particularly so in paediatric dermatologicals due to the growing consumer concerns over the use of endocrine disrupters. Natural solutions such as oleo-calcaire (limestone liniment) are set to take off, as well as brands positioned as natural and organic.
Sanofi, the leader in overall consumer health, also leads paediatric consumer health, but with a much bigger share of sales, accounting for almost a quarter of value in 2019. However, its share has been declining slightly in recent years due to Mitosyl’s falling sales, with this brand having been caught up in the scandal about endocrine disruptors.
Merck continued to be the strong leader in the large paediatric vitamins and dietary supplements category through its Bion 3 Junior range. It is followed by Laboratoires Arkopharma with its Azinc Junior brand.
Many players are still reluctant to invest in any great amount of innovation in what are generally still small, risky and thus rarely profitable niche areas in paediatric consumer health. In addition, manufacturers often focus on medical devices, which are often not included under the Euromonitor International definitions for the consumer health market, for example saline solutions for children.
Files are delivered directly into your account within a few minutes of purchase.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.
Files are delivered directly into your account within a few minutes of purchase.
Discover the latest market trends and uncover sources of future market growth for the Paediatric Consumer Health industry in France with research from Euromonitor's team of in-country analysts.
Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.
If you're in the Paediatric Consumer Health industry in France, our research will save you time and money while empowering you to make informed, profitable decisions.
The Paediatric Consumer Health in France market research report includes:
Our market research reports answer questions such as:
This industry report originates from Passport:
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.